ROCO
6527
Market cap58mUSD
Oct 08, Last price
74.00TWD
1D
-1.33%
1Q
2.21%
Jan 2017
78.61%
IPO
66.70%
Name
Crystalvue Medical Corp
Chart & performance
P/E
12.76
P/S
1.98
EPS
5.80
Div yield, %
3.04%
Shrs. gr., 5y
-0.22%
Rev. gr., 5y
13.48%
Revenues
949m
+9.33%
Net income
147m
+15.59%
CFO
139m
-9.10%
Dividend
Jul 21, 20262.9 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Taoyuan City, Taiwan, and established in 2009, Crystalvue Medical Corporation operates internationally, specializing in the design, production, and distribution of ophthalmic medical devices. Their comprehensive product range encompasses instruments like retinal cameras, tonometers, and lens edgers, in addition to various gastroenterology provisions.
Key people
Wensen Liao
Deputy General Manager · since 2017
Mengxin Yan
Deputy General Manager · since 2010
Chung Ping Chuang
General Manager, Acting Head of Finance & Accounting, Acting Corporate Governance Officer, Director · since 2025
Chongyi Li
Chairman of the Board, Chief Strategy Officer · since 2025
Tianhao Wang
Director · since 2025
Director · since 2025
Independent Director · since 2024
Independent Director · since 2015
Fuqi Xiang
Independent Director · since 2024
Shiqi Zhou
Independent Director · since 2021
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||